Penning L I F, de Bie R A, Walenkamp G H I M
Maastricht University Medical Centre Research School CAPHRI, Department of Orthopaedic Surgery, PO Box 5800, 6202 AZ Maastricht, The Netherlands.
J Bone Joint Surg Br. 2012 Sep;94(9):1246-52. doi: 10.1302/0301-620X.94B9.28750.
A total of 159 patients (84 women and 75 men, mean age of 53 (20 to 87)) with subacromial impingement were randomised to treatment with subacromial injections using lidocaine with one of hyaluronic acid (51 patients), corticosteroid (53 patients) or placebo (55 patients). Patients were followed up for 26 weeks. The primary outcome was pain on a visual analogue score (VAS), and secondary outcomes included the Constant Murley score, shoulder pain score, functional mobility score, shoulder disability questionnaire and pain-specific disability score. The different outcome measures showed similar results. After three, six and 12 weeks corticosteroid injections were superior to hyaluronic acid injections and only at six weeks significantly better than placebo injections. The mean short-term reduction in pain on the VAS score at 12 weeks was 7% (SD 2.7; 97.5% confidence interval (CI) 0.207 to 1.55; p = 0.084) in the hyaluronic acid group, 28% (SD 2.8; 97.5% CI 1.86 to 3.65; p < 0.001) in the corticosteroid group and 23% (SD 3.23; 97.5% CI 1.25 to 3.26; p < 0.001) in the placebo group. At 26 weeks there was a reduction in pain in 63% (32 of 51) of patients in the hyaluronic acid group, 72% (38 of 53) of those in the corticosteroid group and 69% (38 of 55) of those in the placebo group. We were not able to show a convincing benefit from hyaluronic acid injections compared with corticosteroid or placebo injections. Corticosteroid injections produced a significant reduction in pain in the short term (three to 12 weeks), but in the long term the placebo injection produced the best results.
共有159例肩峰下撞击综合征患者(84例女性,75例男性,平均年龄53岁(20至87岁))被随机分为三组,分别接受含透明质酸的利多卡因肩峰下注射治疗(51例患者)、皮质类固醇注射治疗(53例患者)或安慰剂注射治疗(55例患者)。对患者进行了26周的随访。主要结局指标为视觉模拟评分法(VAS)疼痛评分,次要结局指标包括Constant Murley评分、肩部疼痛评分、功能活动评分、肩部残疾问卷和疼痛特异性残疾评分。不同的结局指标显示出相似的结果。在3周、6周和12周时,皮质类固醇注射优于透明质酸注射,且仅在6周时显著优于安慰剂注射。透明质酸组在12周时VAS评分的平均短期疼痛减轻为7%(标准差2.7;97.5%置信区间(CI)0.207至1.55;p = 0.084),皮质类固醇组为28%(标准差2.8;97.5%CI 1.86至3.65;p < 0.001),安慰剂组为23%(标准差3.23;97.5%CI 1.25至3.26;p < 0.001)。在26周时,透明质酸组63%(51例中的32例)的患者疼痛减轻,皮质类固醇组72%(53例中的38例)的患者疼痛减轻,安慰剂组69%(55例中的38例)的患者疼痛减轻。与皮质类固醇或安慰剂注射相比,我们未能证明透明质酸注射有令人信服的益处。皮质类固醇注射在短期内(3至12周)能显著减轻疼痛,但从长期来看,安慰剂注射效果最佳。